Updated:
Anteis
Anteis, a Swiss biomedical manufacturer owned by Merz Aesthetics, produces Belotero dermal fillers sold in over 90 countries.
Anteis
General information
Firm type
other
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
Switzerland
City
Plan-les-Ouates
Corporate office
Plan-les-Ouates, Switzerland
Additional offices
Lonay, Switzerland
Sector focus
Frequently asked questions
Who owns Anteis?
Anteis is owned by Merz Aesthetics, a subsidiary of the Merz Group, a German healthcare company. Anteis functions as a manufacturing and R&D subsidiary, not an independent investment firm (per Merz Aesthetics, 2025).
Does Anteis make investments in external companies or funds?
Anteis does not appear to make external investments. Its capital deployment is limited to internal R&D and production of aesthetic medical devices. No public record shows fund commitments, direct deals, or co-investments by Anteis.
What products does Anteis manufacture?
Anteis develops and produces injectable biomedical devices for aesthetics, including the Belotero line of dermal fillers, resorbable implants, and skin hydration gels. These products are sold through Merz Aesthetics in over 90 countries (per Merz Aesthetics, 2025).
Where are Anteis's operations located?
Anteis has two sites in Switzerland: its registered headquarters in Plan-les-Ouates and its main operational site in Lonay. The company does not have disclosed offices outside Switzerland.
How is Anteis structured relative to a family office?
Anteis is not a family office or asset manager. It is an operating company—a biomedical manufacturer owned by a larger corporate group, Merz Aesthetics. Its structure lacks investment committees, external capital raising, or portfolio management typical of family offices.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: